Filing Flows › Arbutus Biopharma (ABUS) › Q1 2026
Arbutus Biopharma (ABUS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Arbutus Biopharma (ABUS) reported revenue of $179M for the first quarter 2026 (Q1 2026), up 102-fold from a year earlier and up 170-fold from the quarter before. Operating margin was 94.3%, net earnings $170M (94.7% of revenue).
Arbutus Biopharma, Q1 2026: revenue $179M (102× year over year), operating margin 94.3%, net earnings $170M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $179M | 170× | 102× |
| Operating profit | $169M | — | — |
| Net earnings | $170M | — | — |
| Operating cash flow | −$8.1M | — | — |
What changed
Revenue was $179.1M in Q1 2026, up 10055% year over year and up 16943% from the previous quarter. Revenue from collaborations and licenses was the largest line at 100% of revenue. Collaborations and licenses declined 84%.
Operating profit was $168.9M, a 94.3% margin (up 1551.2 points year over year). Total costs fell 63% while revenue rose 10055%. Net earnings were $169.7M. The effective tax rate was 0.0%.
Operating cash flow was −$8.1M. Non-cash charges added back $11K of depreciation and amortization and $1.4M of share-based compensation. Working capital and other items used $179.2M.
Questions
What was Arbutus Biopharma's revenue in the first quarter 2026?
Arbutus Biopharma (ABUS) reported revenue of $179M for the first quarter 2026 (Q1 2026), up 102-fold from a year earlier and up 170-fold from the quarter before.
Was Arbutus Biopharma profitable in the first quarter 2026?
Operating profit was $169M (94.3% of revenue) and net earnings $170M.
Source: Arbutus Biopharma 10-Q on SEC EDGAR.